Chromacity funding news – Edinburgh-based Chromacity Secures €1.18 Million in New Funding

Chromacity, an Edinburgh-based company, creates and produces infrared lasers that are ultrafast, tuneable, compact, and reasonably priced. These lasers are utilised in quantum applications, microscopy, spectroscopy, and advanced research.

Chromacity is rapidly expanding its global clientele, which already includes the US Air Force, Harvard University, and Sandia National Laboratories. Prior to now, sales in the UK were concentrated on the university sector; now, their newly developed healthcare-focused product is opening up far more commercial opportunities.

Read also - Credo AI funding news – Brussels-based Credo AI Secures €19.4 Million in Funding

With its inexpensive light source for medical diagnostics, such as biological imaging of collagen, which can provide an early diagnosis for a variety of medical disorders, the company's new "920" product is well-suited for medical imaging.

By producing a light pulse with a duration of up to 100 femtoseconds, the '920' aids in illuminating collagen, the main component of the body's muscles, bones, tendons, ligaments, and other connective tissues, enabling researchers to delve within living cells.

One quadrillionth, or one millionth of one billionth of a second, is equal to a femtosecond. The user benefits greatly from the short pulse because there is less collateral damage to the sample being analysed due to the short duration of the laser's operation.

In order to support the transition to net zero agriculture, Chromacity has also received funding from the Innovate UK program to develop a new monitoring tool that will use its patented infra-red laser technology to measure important greenhouse gases like ammonia and ethane in real-time.

Robert Black, an accomplished executive and non-executive director with experience in the photonics, IT, and robotics industries; Richard Laming, a successful academic and founder of technology businesses spanning optoelectronics, MEMS, and electronics; and investor director Graham Miller, Director of Global Sales and Business Development at Agilent Technologies, round out the board of directors that Julian joins.

Julian Hayes, CEO at Chromacity, said: “Designing and manufacturing state-of-the-art ultrafast infra-red lasers brings huge value and efficiencies to the global healthcare market. Our new ‘920’ builds on a decade of research and IP development to extend our product roadmap.”

Andrew McNeill from Eos and Susie Fisher from Kelvin Capital, added: “Chromacity is at the forefront of knowledge-intensive engineering in Scotland and both Eos and Kelvin, with co-investment from Scottish Enterprise are proud to have helped them develop their range. The coming years are now focussed on engaging in new UK and international markets, including biological imaging. The funding from the Innovate UK programme also highlights the broad applications of the company’s patented technology in agricultural sustainability.”

Kerry Sharp, Director of Entrepreneurship and Investment at Scottish Enterprise, commented: “Chromacity is a fantastic example of an innovative company with global ambitions, capable of scaling quickly. As an existing investor, we’re excited to see the company make progress towards its goals.”

About Chromacity

Chromacity is creating the next generation of ultrafast laser sources for use in global industry and scientific research. A variety of fixed wavelength and tunable laser sources have been developed by combining solid-state and fiber-based technologies. Their IP-protected manufacturing expertise allows Chromacity to deliver systems at competitive price points without sacrificing performance, while their study and small systems guarantee great stability and excellent efficiency.